Overview

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients

Status:
Completed

Trial end date:
2021-10-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare progression-free survival (PFS) in patients with advanced/metastatic breast cancer who have a BRCA mutation when treated with niraparib as compared to those treated with physician's choice

Phase:

Phase 3

Details

Lead Sponsor:

Tesaro, Inc.

Collaborators:

Breast International Group
European Organisation for Research and Treatment of Cancer - EORTC
Facing Our Risk of Cancer Empowered
Myriad Genetic Laboratories, Inc.
Sarah Cannon
US Oncology Research

Treatments:

Niraparib